CPM
RXRX icon

Connective Portfolio Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Connective Portfolio Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-33,000
Closed -$252K – 50
2023
Q3 		$252K Buy
+33,000
New +$329K 0.77% 34

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Connective Portfolio Management's RXRX Position: Q4 2023 in Review

Connective Portfolio Management sold out of Recursion Pharmaceuticals (RXRX) in Q4 2023, closing a stake of 33,000 shares — an estimated $252K sold.

Connective Portfolio Management first reported a position in RXRX in Q3 2023 and held it in 1 quarter. The position peaked at $252K in Q3 2023. 199 funds tracked by Wall St. Rank hold RXRX as of Q4 2023.

  • Connective Portfolio Management reported no remaining Recursion Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Connective Portfolio Management sold 33,000 Recursion Pharmaceuticals shares in Q4 2023, an estimated $252K.
  • Connective Portfolio Management first reported a position in Recursion Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Connective Portfolio Management's Recursion Pharmaceuticals position peaked at $252K in Q3 2023.
  • 199 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2023.

Based on Connective Portfolio Management's 13F filing for Q4 2023, filed 17 Jan 2024.